Real world hospital costs associated with nab-paclitaxel plus gemcitabine (nab-P plus G) and FOLFIRINOX (FFX) as first line (1 L) treatment (tx) for metastatic pancreatic adenocarcinoma (MPAC).

被引：2
|
作者：
Kim, George P.
Parisi, Monika
Patel, Manish
Belk, Kathy
机构：
[1] 21 Century Oncol Jacksonville, Jacksonville, FL USA
[2] Celgene, Summit, NJ USA
[3] MedAssets, Alpharetta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e15741
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15741
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Real-world analysis of treatment patterns examining nab-Paclitaxel plus Gemcitabine (nab-P plus G) versus FOLFIRINOX (FFX) in first-line (10 treatment (tx) of metastatic pancreatic adenocarcinoma (MPAC) in a US community oncology setting
    Braiteh, Fadi S.
    Patel, Manish
    Parisi, Monika
    Ni, Quanhong
    Park, Si Yeon
    Faria, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Treatment outcomes with first-line (1L) nab-Paclitaxel plus gemcitabine (AG) and FOLFIRINOX (FFX) in metastatic pancreatic adenocarcinoma (mPAC).
    Cartwright, Thomas H.
    Parisi, Monika
    Espirito, Janet L.
    Wilson, Thomas
    Pelletier, Corey
    Patel, Manish
    Babiker, Hani M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and gemcitabine plus nab-paclitaxel (NabG).
    Schmidt, Shannon Leah
    Durkal, Vipal
    Jayavalsan, Shinoj Pattali
    Thomas, James P.
    Ritch, Paul S.
    Erickson, Beth
    Christians, Kathleen K.
    Tsai, Susan
    Evans, Douglas B.
    George, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [4] Real-world analysis of treatment patterns examining nab-Paclitaxel plus gemcitabine (nab-P plus G) versus gemcitabine monotherapy (G) in first-line treatment of metastatic pancreatic adenocarcinoma (MPAC) in a US community oncology setting
    Braiteh, Fadi S.
    Patel, Manish
    Parisi, Monika
    Ni, Quanhong
    Park, Si Yeon
    Faria, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC)
    Chiorean, E. G.
    Cheung, W. Y.
    Giordano, G.
    Kim, G.
    Al-Batran, S-E.
    ANNALS OF ONCOLOGY, 2018, 29 : 245 - 246
  • [6] Optimized economic evaluation for the United States (US) of nab-paclitaxel plus gemcitabine (NAB-P plus GEM) FOLFIRINOX (FFX), and gemcitabine (GEM) as first-line treatment for metastatic pancreatic cancer (mPDA)
    Gharaibeh, Mahdi
    McBride, Ali
    Bootman, J. Lyle
    Patel, Hitendra
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine (nab-P plus G) versus FOLFIRINOX (FFX) in first-line treatment of advanced pancreatic adenocarcinoma (PDAC) in a US community oncology setting.
    Braiteh, Fadi S.
    Patel, Manish
    Parisi, Monika
    Ni, Quanhong
    Park, Si Yeon
    Faria, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [8] FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study
    Servetto, Alberto
    Santaniello, Antonio
    Napolitano, Fabiana
    Foschini, Francesca
    Marciano, Roberta
    Cascetta, Priscilla
    Amato, Anna Rita
    Augurio, Maria Rosaria
    Maresca, Lucia
    De Placido, Pietro
    De Placido, Sabino
    Formisano, Luigi
    Bianco, Roberto
    FUTURE ONCOLOGY, 2022, 18 (21) : 2643 - 2654
  • [9] Second-line treatment of modified FOLFIRINOX or nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma
    Ozaka, Masato
    Sasaki, Takashi
    Yamada, Ikuhiro
    Kanata, Ryo
    Akiyama, Dai
    Katagiri, Tomoko
    Takano, Koichi
    Matsuyama, Masato
    Sasahira, Naoki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [10] Economic evaluation for the United States (US) of gemcitabine (GEM), nab-paclitaxel plus gemcitabine (NAB-P plus GEM), and FOLFIRINOX as first-line treatment for metastatic pancreatic cancer (MPC)
    Gharaibeh, Mahdi
    McBride, Ali
    Bootman, J. Lyle
    Cranmer, Lee D.
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345